According to the new research report published by Precedence Research, titled “mRNA Therapeutics Market (By Application: Rare Genetic Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Others; By Type: Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs; By End User: Hospitals & Clinics, Research Organizations, Other) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global mRNA therapeutics market size is expected to be worth around US$ 128.14billion by 2030 and is poised to record a yearly growth rate of 13.03% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on mRNA therapeutics market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall mRNA therapeutics market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2118
The study also provides important advancements in organic and inorganic growth strategies in the worldwide mRNA therapeutics market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of mRNA therapeutics market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Market Scope
Report Scope of the mRNA therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 48.1 Billion |
| Market Size by 2030 | USD 128.14 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 13.03% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Application, Type, End User, and Geography |
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the mRNA therapeutics market.
Some of the prominent players in the mRNA therapeutics market include:
- Alnylam Pharmaceuticals
- Arcturus Therapeutics
- Argos Therapeutics Inc.
- AstraZeneca plc.
- BioNTech SE
- CRISPR Therapeutics AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- GSK plc.
- IN-CELL-ART
- Ionis Pharmaceuticals, Inc
- Moderna Therapeutics
- Nutcracker
- Pfizer Inc.
- Sangamo Therapeutics, Inc.
- Sanofi AG
- Sarepta Therapeutics
- Tiba Biotech
- Translate Bio, Inc.
Market Segmentations
By Application
- Rare Genetic Diseases
- Oncology
- Respiratory Diseases
- Infectious Diseases
- Others
By Type
- Prophylactic Vaccines
- Therapeutic Vaccines
- Therapeutic Drugs
By End User
- Hospitals & Clinics
- Research Organizations
- Other
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, segment, and project the global market size for mRNA therapeutics market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyze the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyze their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyze the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on MRNA Therapeutics Market
5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global MRNA Therapeutics Market, By Application
8.1. MRNA Therapeutics Market, by Application, 2022-2030
8.1.1 Rare Genetic Diseases
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Respiratory Diseases
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Infectious Diseases
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global MRNA Therapeutics Market, By Type
9.1. MRNA Therapeutics Market, by Type, 2022-2030
9.1.1. Prophylactic Vaccines
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Therapeutic Vaccines
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Therapeutic Drugs
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global MRNA Therapeutics Market, By End User
10.1. MRNA Therapeutics Market, by End User, 2022-2030
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Organizations
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Other
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 12. Company Profiles
12.1. Alnylam Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Arcturus Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Argos Therapeutics Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BioNTech SE
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CRISPR Therapeutics AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Curevac AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Etherna Immunotherapies
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ethris GMBH
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GSK plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global mRNA therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for mRNA therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
